SOPH

SOPHiA Genetics Jumps on Q2 Beat, AstraZeneca Deal as Volume Spikes

SOPH volume surged to 4.5x average after a Q2 revenue beat and AstraZeneca diagnostics deal, though a wider EPS miss and recent insider selling flag risk in this unclassified-sector name.